3 May 2013 07:00
News Release
3 May 2013
Consort Medical plc
King Vision deferred consideration update
Consort Medical plc ("Consort" or "The Group") (LSE: CSRT), notes the Q2 Interim report issued 2 May 2013 by Ambu A/S for the period 1 October 2012 to 31 March 2013.
In the report, Ambu makes the following commentary about the development of the King Vision product:
"The launch of a new generation of the King Vision product is going according to plan and is expected to take place in the current financial year. As previously announced, this will result in a milestone payment to Consort Medical of USD 10m."
Ambu's current financial year ends on 30 September 2013.
Consort Medical will announce its full year results for the year ended 30 April 2013 on 13 June 2013.
-Ends-
Enquiries:
ConsortJonathan Glenn - Chief Executive Richard Cotton - Finance Director | Tel: +44 1442 867920 |
Brunswick Group Jon Coles Amie Gramlick | Tel: +44 20 7404 5959
|
Consort Medical plc is an international medical devices company, focused on developing and manufacturing disposable medical devices for drug delivery. The principal business of the Company is the management of Bespak, a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.
The Group has facilities in King's Lynn, Cambridge, Nelson and Hemel Hempstead in the UK. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT). The Group's website address is www.consortmedical.com.